|
|
|
|
|
|
|
|
Note: Trastuzumab is also known as Herceptin "Based on these considerations, it would be interesting if Extra and colleagues could reanalyze their data by distinguishing patients stopping trastuzumab according to whether or not they had "equal opportunities" to patients continuing trastuzumab beyond progression." (The Oncologist) Editor's note: Dr. Extra was invited to reply but declined comment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.